Prof. Dr. Raja Atreya

Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen

Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn’s disease and a history of cerebral venous sinus thrombosis (2026) Fousekis F, Ronicke M, Sollfrank L, Rech J, Berking C, Neurath MF, Sticherling M, Atreya R Journal article Intestinal barrier healing is superior to transmural healing to prevent disease progression in clinical remittent patients with inflammatory bowel disease (2026) Orlemann T, Zimmermann D, Hübner H, Atreya R, Bodenschatz J, Noviello D, Vitali F, et al. Journal article Filamin a binds deleted in liver cancer 1 (DLC1) to promote its tumor suppressor activity and inhibit the SRF coactivator MRTF-A (2026) Sergeev M, Meier M, Wohlleben P, Rupprecht L, Kupraszewicz-Hutzler M, Hilgers KF, Hartner A, et al. Journal article Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis (2026) Atreya R, Neurath M Journal article Efficacy and health-related quality of life associated with second-line vedolizumab after first-line treatment with one anti-TNF in patients with ulcerative colitis: a meta-analysis of the GEMINI-1 and VISIBLE-1 trials (2026) Atreya R, Kirchgesner J, Cheah Z, Biedermann P, Bakker L, Meyer M, Raine T Journal article JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease (2025) Fousekis FS, Jefremow A, Katsanos KH, Neurath M, Atreya R Journal article, Review article Resolving Loss of Response to Ustekinumab in Crohn’s Disease: POWER Through or Switch Treatment? (2025) Noviello D, Atreya R, Noor NM Journal article An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease (2025) Solitano V, Hanžel J, Ma C, Battat R, Raine T, Siegmund B, Peyrin-Biroulet L, et al. Journal article Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis (2025) Ferrante M, Peyrin-Biroulet L, Arkkila P, Armuzzi A, Colombel JF, Danese S, Faggiani R, et al. Journal article CD19 CAR T-Cell Therapy in Multidrug-Resistant Ulcerative Colitis (2025) Müller F, Atreya R, Völkl S, Aigner M, Kretschmann S, Kharboutli S, Leppkes M, et al. Journal article